Bisphosphonate Osteonecrosis May Be Class Effect, FDA Safety Review Says
This article was originally published in The Pink Sheet Daily
Executive Summary
ODS review finds 139 cases of osteonecrosis in patients receiving IV bisphosphonates Zometa and Aredia, or oral drugs Fosamax and Actonel, although many fewer are found with oral drugs vs. IV. Zometa and Aredia are subject of March 4 oncologic drugs advisory committee meeting on osteonecrosis of the jaw.